Pulse Alternative
Trading

HCA Healthcare (HCA) Stock Still Trades At A Discount Despite A 52% Return


Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

HCA Healthcare stock has fallen sharply in the short term, yet over five years it is still in positive territory and currently screens as undervalued on several valuation checks. This sets up a clear tension between recent sentiment and longer term returns.

  • HCA Healthcare has returned 52.3% over the past five years, so long term holders remain ahead even after recent share price pressure.

  • Expectations around HCA Healthcare’s use of scale and AI tools to support care quality can help the investment case, while a rising load of uninsured patients and union related staffing pressures may weigh on profitability and investor confidence.

  • On Simply Wall St’s broader checks, HCA Healthcare screens as inexpensive across the board, with the company looking undervalued on 6 of 6 valuation measures.

For investors, the debate is whether the recent weakness in HCA Healthcare’s share price now offers a genuine discount or simply reflects the financial hit from a tougher payer mix and operating backdrop.

Find out why HCA Healthcare’s -1.5% return over the last year is lagging behind its peers.

Is HCA Healthcare Still Cheap on Earnings?

The P/E ratio is a useful way to see how much investors are paying for HCA Healthcare’s earnings today. HCA Healthcare trades on a P/E of about 11.9x, which is below both the broader Healthcare industry average of around 25.1x and the peer group average of roughly 15.0x.

On Simply Wall St’s fair multiple framework, HCA Healthcare’s P/E would be closer to 26.7x given its mix of growth, margins, size and risks. The current 11.9x therefore implies a wide discount to that reference point. Despite the recent cut to 2026 earnings guidance and concerns around a heavier uninsured patient load, the stock price still values HCA Healthcare at a level that screens as inexpensive relative to its earnings power on this model.

Overall, HCA Healthcare stock appears undervalued on the P/E multiple compared with both its industry and the fair ratio estimate.

NYSE:HCA P/E Ratio as at Jul 2026
NYSE:HCA P/E Ratio as at Jul 2026

See what the numbers say about this price — find out in our valuation breakdown.

The HCA Healthcare Narrative: What Would Justify Today’s Price?

Simply Wall St Narratives for HCA Healthcare sit on the company’s Community page and act as the bridge from the valuation puzzle above by explaining which paths for HCA Healthcare’s growth, margins and earnings would align with a meaningfully higher or lower stock price than today. Where a single ratio or model gives one number, these narratives describe the future that number is based on so you can watch how HCA Healthcare’s actual results compare over time.

One of the top community narratives on HCA Healthcare: 42% undervalued

“In a market that often swings between hype and fear, HCA Healthcare (NYSE: HCA) stands out for a different reason: consistency…”

Read one of the top narratives on HCA Healthcare

Do you think there’s more to the story for HCA Healthcare? Head over to our Community to see what others are saying!

The Bottom Line

HCA Healthcare currently screens as undervalued on market multiples, with its P/E sitting well below both sector peers and the fair multiple estimate implied by its fundamentals. That discount appears appealing if you think the company can manage uninsured patient exposure and staffing pressures without a lasting hit to margins. If those concerns prove more persistent, the lower multiple may simply reflect a reset in what investors are willing to pay. The key question from here is whether HCA Healthcare can sustain earnings quality well enough for that valuation gap to close rather than become a longer term value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include HCA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com



Source link

Related posts

EBOS Group Ltd stock (NZEBOE0001S6): Healthcare distributor in focus after latest trading update

George

Elderly man duped of Rs 2.2 crore in auto trading cyberfraud | Hubballi News

George

NBA trade tracker: Updates for every deal of the 2026 offseason

George

Leave a Comment